In this episode, we explore the journey of Accellta, an Israeli company founded 12 years ago with a mission to revolutionize the cultivation and manufacturing of stem cells. Stem cells, known for their ability to differentiate into various specialized cell types and undergo unlimited cell divisions, hold immense potential in the biotech and food-tech industries.

Accellta's proprietary 3D suspension culture platform addresses the critical scalability bottleneck in stem cell production, enabling large-scale, cost-effective manufacturing. Their innovative approach ensures affordable end-products, including chemically defined media and proprietary stable cell lines derived from humans, aquatic animals, and farm animals.

Since 2018, Accellta has achieved stable profitability through its diverse services and partnerships with global industry leaders. 

Now, the company seeks $5 million to scale up its capabilities for the evolving food tech industry.

If you are an investor looking for new opportunities in the food tech space, this podcast is for you.

In this episode, we sit down with Avishai Ben Tovim, CEO of MDI, a company founded in 2019. MDI has developed a groundbreaking risk analysis system for polypharmacy patients, designed to manage complex cases and provide accurate clinical recommendations for treatment optimization and risk mitigation.

Despite increasing efforts to prevent adverse drug reactions over the past decade, drug-induced hospitalizations and mortality rates continue to rise. MDI's medication management platform addresses this issue by scaling up the prevention process, helping physicians and payors avoid the clinical and financial consequences of drug-related adverse events.

The platform conducts comprehensive drug-related risk analyses for entire populations, identifying at-risk individuals and providing financial projections even before conducting per-patient analyses. By analyzing thousands of pharmacological and medical parameters, MDI's algorithms enable payors and physicians to pinpoint precise and immediate health risks, generating evidence-based clinical recommendations to reduce these risks.

MDI's mission is to enable Value Based Care, focusing on clinical quality and cost reduction. Join us as we discuss MDI's innovative solution, the validation they generated, , and their future goals.

🎧 This Podcast is also available in a video format on “The Healthcare Stage” YouTube channel

In this episode, we delve into the groundbreaking innovations of Swift Duct, an Israeli medical device company founded in 2020, with CEO Samer Abboud. Swift Duct is on a mission to transform Endoscopic retrograde cholangio-pancreatography (ERCP), a vital procedure aimed at and treating detecting biliary and pancreatic duct blockages.

Through a captivating discussion, we discuss how Swift Duct's cutting-edge navigation solution aims to revolutionize ERCP, promising easier, faster, and safer procedures. With a catheter boasting unique bending capabilities and a sensor-equipped guidewire, the company aims to streamline the process, reduce trial and error, and ultimately mitigate healthcare costs and patient suffering.

We discuss Swift Duct's journey from seed funding to successfully demonstrating their technology's proof of concept in preclinical trials. Join us to explore how Swift Duct's innovative approach stands to benefit over 2 million ERCP procedures annually and why this venture presents a compelling investment opportunity in the MedTech landscape.

If you're an investor seeking new prospects in the MedTech sector, tune in to gain insights into the potential future of ERCP and the promising advancements brought forth by Swift Duct.

Listen now on Spotify and Apple Podcast or view on “the Healthcare Stage" YouTuve channel, and stay ahead in the ever-evolving world of MedTech! 🚀

#TheHealthcareStage #MedTech #HealthcareInnovation  #ERCP #VC #Investment #Startup #SwiftDuct

In this episode, we delve into a fascinating conversation with Elad Yakobson, the CEO of Pulsar Medtech, an Israeli startup making waves in the MedTech industry. Tune in to discover how Pulsar Medtech is revolutionizing bone healing with its innovative Bone Growth Stimulation devices.

Pulsar Medtech's devices offer a promising solution to enhance patient comfort and compliance, addressing challenges commonly faced with existing bone growth stimulation devices. With lightweight patches designed for improved comfort and adherence, Pulsar Medtech is paving the way for better clinical outcomes.

Discover the safety and efficacy of Pulsar Medtech's devices, backed by rigorous clinical studies. Find out how they're gearing up for a pivotal study in the US in 2024 and their plans to raise $6-8 million to facilitate FDA approval and market penetration.

For investors seeking opportunities in the MedTech space, this podcast provides valuable insights into Pulsar Medtech's innovative approach and future prospects.

Listen now on Spotify and Apple Podcast or view on "The Healthcare Stage" YouTube channel, and stay ahead in the ever-evolving world of MedTech! 🚀

#TheHealthcareStage #MedTech #HealthcareInnovation #BoneHealing #Bonegrowthstimulation #Fractures #orthopedicpatients #VC #Investment #Startup #PulsarMedtech

This episode is dedicated to a conversation with Yaniv Glazer, The CEO of Golden Heart Flower, an early-stage Israeli pharmaceutical company dedicated to addressing rare diseases. Specifically, we explore their focus on Adult Polyglucosan Body Disease (APBD) and their development of GHF201, a small molecule drug. GHF201 shows promise beyond APBD, potentially impacting various lysosomal storage diseases by enhancing lysosomal activity.

With approval for compassionate use from the Israeli Ministry of Health, the company has gathered 5 years of clinical data from 3 APBD patients, indicating both safety and efficacy.

Currently seeking $10M in funding to complete CMC and toxicology studies, Golden Heart Flower aims to initiate its first clinical study. For pharmaceutical investors interested in the rare disease sector, this podcast offers a sober analysis of the company's progress and investment prospects.

This episode is dedicated to a conversation with Avishay Sidlesky, The CEO of VTM technologies, an Israeli medical device startup.

In the battle against colorectal cancer (CRC), VTM Technologies developed an innovative laser-based Virtual Tape-Measure. This new tool provides an assessment of polyp size during colonoscopy procedures, offering unparalleled accuracy and objectivity. With FDA approval already secured, VTM Technologies wishes to transform the landscape of CRC screening and surveillance.

Colonoscopy, a cornerstone of CRC prevention, holds significant importance in detecting and monitoring the disease, which ranks as the second leading cause of cancer death globally. The accuracy of follow-up colonoscopy guidelines hinges upon precise measurements of polyp size and number. Yet, current methods rely on subjective assessments by gastroenterologists, leaving room for error and potentially dire consequences for patients.

The implications of inaccuracies in polyp size assessment are profound. Overestimation may trigger unnecessarily early follow-up colonoscopies, subjecting patients to discomfort and straining healthcare resources. Conversely, underestimation poses a grave risk, delaying cancer diagnosis and compromising survival rates.

VTM Technologies' system addresses these critical challenges head-on. By providing objective measurements, it eliminates the pitfalls of subjective assessment, promising to save lives and reduce healthcare costs.

As VTM Technologies embarks on its journey to commercialize the new device, it seeks strategic partnerships and investment to propel its mission forward.

#TheHealthcareStage #Colonoscopy #coloncancer #VTMtechnologies

The podcast is also available on YouTube at The Healthcare Stage YouTube channel

https://www.youtube.com/@TheHealthcareStage

In this episode, we're zeroing in on how precision oncology principles are revolutionizing our understanding of anesthetic and analgesic drugs and their potential influence on cancer outcomes. My guest, Professor Joshua Mincer from the Memorial Sloan Kettering Cancer Center in New York, unveils cutting-edge research applying these principles to gauge the effects of anesthetics and painkillers on cancer patient outcomes, viewed through the prism of patient-specific omics data. This line of research is particularly important since most anesthetic and anti-pain medications are generic drugs, hinting at the possibility of boosting patient outcomes without the burden of extra costs. Moreover, we'll explore the horizon of clinical development for innovative anti-pain and anticancer immunotherapies and delve into the critical evaluations needed for the combined use of new anticancer and pain management drugs, aiming to illuminate the future pathways for improving cancer outcomes."

The podcast episodes are available at The Healthcare Stage YouTube channel, on Spotify and Apple podcast:

https://open.spotify.com/show/0e3gsjyULZCSLlpR9hx4PR

https://podcasts.apple.com/il/podcast/the-healthcare-stage/id1723753563

#TheHealthCareStage #Percisionmedicine #cancer #MSK #Analgesics #anasthetics #antipainmedication #Oncology

This episode is dedicated to ClearCut medical, a commercial-stage medical device company based in Israel. The company developed the @ClearCoast™ system, a novel portable @MRI scanner for real-time intra-operative margin assessment of excised tissue during Breast Conserving Surgery (BCS), also known as lumpectomy.

With the ClearCoast™ @MRI system the surgeon can instantly identify, while at the operating room, marginal areas suspected to be malignant without special training for interpretation. As a result, there is no need to wait for pathologist assessment, and the surgeon can immediately proceed to remove the remaining malignant tissue at the margins without waiting days for a pathology report. Traditionally, the process to identify cancerous cells near the margins of a removed breast tumor involves waiting for a pathological examination, which can take several days to weeks after the surgery. Following pathological assessment, a second surgery is recommended in about 25% of cases when malignant cells are found at the margins, leading to significant costs, inefficiencies in the healthcare system, and most importantly, added emotional distress for patients.

The company launched the ClearCoast™ system in Europe in 2022 and started sales in 2023. They are currently working towards an FDA approval. Up until now ClearCut raised $23M and is now planning to raise $15M. The proceeds will be used for supporting sales in Europe, attaining FDA approval and exploring the system in additional indications.

This episode is available at The Healthcare Stage YouTube channel,  Spotify and Apple podcast.

This episode is dedicated to an Israeli food-tech startup named Exosomm, established in 2021. The company’s first product is a proprietary formula for Inflammatory Bowel Diseases (IBD), containing milk exosomes derived from cow milk.

The scientific basis for this company originates from many years of research conducted at Hadassah Medical Center, which generated robust evidence demonstrating the anti-inflammatory activity of mammals’ milk-derived exosomes. These findings were shown in multiple preclinical studies in both IBD models but also in additional indications.

Their first product, regulated as food, is intended for use in ulcerative colitis and Crohn’s patients, for both maintenance and flare periods, and is aimed at reducing gut inflammation and improve the patient’s quality of life.

As of company establishment and up to the beginning of 2024, the company was able to achieve significant milestones, Including the development of exosomes-extraction methodology, important IP, initial regulatory approval, and partnership with Tnuva- a leading food company in Israel which will be their 1st commercial partner in Israel. This agreement also allows Exosomm to extract the exosomes and scale up the production process in Tnuva’s manufacturing facility.

Exosomm raised up until now $1.1M from several Investors including AgFunder, Clalit health services, which owns 60% of the hospitals in Israel and Tnuva, a key player in the Israeli dairy market. They are now looking to raise a bridge round of $1M to achieve their 2024 milestones.

This Episode is dedicated to a conversation with Dr. Idit Lachover-Roth, the principal investigator of the COMEET study- a prospective clinical study conducted in Israel in more than 2000 infants. The primary focus of this study was to explore if early exposure to cow's milk formula (CMF) influences the likelihood of developing IgE-mediated cow's milk allergy (CMA) in infants. The results were revealing: infants who consistently consumed CMF from birth showed a significantly reduced incidence of IgE-mediated CMA compared to those who had only occasional CMF exposure. These findings underscore the importance of both the timing and regularity of CMF exposure in safeguarding infants against IgE-mediated cow's milk allergy. This critical insight may offer a preventative approach to minimize the risk of cow's milk allergy in infants fed with cow milk formula.

The Videocast is available at “The Healthcare Stage” YouTube channel. The audio is available at Apple podcast and Spotify.